What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for the enhancement of efficacy and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy, wherein an initial dose followed by one or more secondary doses of the IL-4R antagonist are to be administered in combination with the SCIT regimen, wherein the initial dose comprising 600 mg of the IL-4R antagonist is to be administered 1 to 14 days prior to the start of the SCIT regimen, wherein each secondary dose comprises 300 mg of the IL-4R antagonist and is to be administered 2 weeks after the immediately preceding dose, and wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.

2. The use of the IL-4R antagonist according to claim 1, wherein the SCIT regimen comprises a grass extract to be administered subcutaneously that is from a grass selected from the group consisting of Timothy, Bahia, Bermuda, Johnson, Kentucky bluegrass, Orchard, Redtop, Rye, Sweet Vernal, Meadow Fescue, and combinations thereof.

3. The use of the IL-4R antagonist according to claim 2, wherein the grass extract is from Timothy grass.

4. The use of the IL-4R antagonist according to any one of claims 1 to 3, wherein the SCIT regimen comprises a cluster SCIT regimen.

5. The use of the IL-4R antagonist according to claim 4, wherein the cluster SCIT regimen comprises an up-titration regimen followed by a maintenance regimen, wherein the up-titration regimen comprises increasing doses of the grass extract over a period of 4 to 12 weeks to be administered and wherein the maintenance regimen comprises one or more maintenance doses of the grass extract to be administered at the highest dose during the up-titration regimen.

6. The use of the IL-4R antagonist according to claim 5, wherein the up-titration regimen comprises increasing doses of the grass extract to be administered over a period of 8 weeks.

7. The use of the IL-4R antagonist according to claim 5 or 6, wherein the maintenance regimen comprises maintenance doses to be administered every 1 to 4 weeks for at least 8 weeks.

8. The use of the IL-4R antagonist according to any one of claims 5 to 7, wherein the up-titration regimen comprises a dose of 1 bioequivalent allergy unit (BAU) to be up-titrated to a dose of 4,000 BAU and wherein the maintenance regimen comprises one or more maintenance doses to be administered at 4,000 BAU.

9. The use of the IL-4R antagonist according to any one of claims 1 to 8, wherein the IL-4R antagonist is to be administered as an initial dose followed by one or more secondary doses, wherein each secondary dose is to be administered 1 to 4 weeks after the immediately preceding dose.

10. The use of the IL-4R antagonist according to any one of claims 1 to 9, wherein the initial dose of the IL-4R antagonist is to be administered from 1 to 7 days before the start of the SCIT regimen.

11. The use of the IL-4R antagonist according to any one of claims 1 to 10, wherein the IL-4R antagonist and the SCIT are not to be administered to the subject on the same day.

12. The use of the IL-4R antagonist according to any one of claims 1 to 11, wherein the enhancement of efficacy and/or tolerability of the SCIT regimen comprises reducing allergic rhinitis symptoms in the subject.

13. The use of the IL-4R antagonist according to any one of claims 1 to 12, wherein the enhancement of efficacy and/or tolerability of the SCIT regimen comprises:

(a) increasing the amount of serum grass allergen-specific IgG4 (sIgG4) in the subject relative to SCIT monotherapy;

(b) decreasing the amount of serum grass allergen-specific IgE (sIgE) in the subject relative to SCIT monotherapy; and/or

(c) increasing the ratio of sIgG4 to sIgE in the subject relative to SCIT monotherapy.

14. The use of the IL-4R antagonist according to any one of claims 1 to 13, wherein the IL-4R antagonist to be administered in combination with the SCIT regimen reduces or inhibits the induction of sIgE during the SCIT up-titration regimen and/or the SCIT maintenance regimen.

15. The use of the IL-4R antagonist according to any one of claims 1 to 14, wherein the IL-4R antagonist to be administered in combination with the SCIT regimen increases the maximum SCIT dose that is tolerated by the subject.

16. The use of the IL-4R antagonist according to any one of claims 1 to 15, wherein the IL-4R antagonist to be administered in combination with the SCIT regimen reduces the use of epinephrine or an oral steroid as a rescue medication.

17. The use of the IL-4R antagonist according to any one of claims 1 to 16, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3; the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the amino acid sequence of SEQ ID NO:5; the LCDR1 comprises the amino acid sequence of SEQ ID NO:6; the LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.

18. The use of the IL-4R antagonist according to any one of claims 1 to 17, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1 and comprises a LCVR comprising the amino acid sequence of SEQ ID NO:2.

19. The use of the IL-4R antagonist according to any one of claims 1 to 18, wherein the anti-IL-4R antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

20. The use of the IL-4R antagonist according to any one of claims 1 to 19, wherein the IL-4R antagonist is dupilumab or a bioequivalent thereof.

21. The use of the IL-4R antagonist according to any one of claims 1 to 20, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, a pen delivery device, and an autoinjector.

22. The use of the IL-4R antagonist according to claim 21, wherein the IL-4R antagonist is contained in a pre-filled syringe.

23. The use of the IL-4R antagonist according to claim 22, wherein the pre-filled syringe is a single-dose pre-filled syringe.

24. The use of the IL-4R antagonist according to claim 21, wherein the IL-4R antagonist is contained in an autoinjector.

25. The use of the IL-4R antagonist according to claim 21, wherein the IL-4R antagonist is contained in a pen delivery device.